SynthesisBMC pregnancy and childbirth2025
Maternal perfluoroalkyl and polyfluoroalkyl substances (PFAS) exposure and preeclampsia: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polyfluoroalkyl and perfluoroalkyl substances (PFAS) are persistent organic pollutants and exposure have been suggested with the risk of developing preeclampsia. Yet, evidence on the associations of PFAS with preeclampsia is still conflicting. Thus, the current study conducted a systematic review and meta-analysis of the epidemiological evidence linking maternal PFAS exposure to preeclampsia. This research methodology involved searching three electronic databases for epidemiological studies, and then conducting a meta-analysis using a random-effects model to analyse the heterogeneity between the studies. The quality and strength of evidence for each exposure-outcome pair was also evaluated, as well as the risk of bias. The search identified 10 potentially eligible studies related to maternal PFAS blood level with preeclampsia, which 7 were ultimately selected. Meta-analysis demonstrated evidence of association between combined PFAS compounds in pregnant mother with preeclampsia with zero heterogeneity (I2=0.0%, Q= 3.09, df= 6, p=0.798). Preeclampsia was found to have moderate association with maternal perfluorooctanoic acid (PFOA) exposure (Test for overall effect: z=2.2, p=0.03; Test for heterogeneity: I2=0.0%, Q= 3.49, df= 6, p=0.745) as well as maternal perfluorooctane sulfonate (PFOS) exposure (Test for overall effect: z=2.5, p=0.01; Test for heterogeneity: I2=0.0%, Q= 3.70, df= 6, p=0.718). This study showed significant associations between PFOA and PFOS exposure with the risk of preeclampsia. However, in-depth investigation is imperative to elucidate the impact of the different concentration and types of PFAS on preeclampsia risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.